Network News
At Heidelberg University Hospital (UKHD), there is a new treatment option for certain patients with severe cardiac arrhythmias: an implantable defibrillator in which the electrode—unlike in conventional defibrillators—is placed outside the heart and blood vessels. This protects the blood vessels. In addition, the system can correct some arrhythmias using mild electrical impulses before an electric […]
read more
Cell Signaling Technology Announces ISO 13485 Certification
Certification enables increased support for partners and customers with industry-leading antibody reagents for commercial applications. Danvers, MA, USA, July 16, 2026–Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced that its Beverly, MA, US and Leiden, NL facilities have achieved ISO 13485:2016 certification for […]
read more
Breakthrough Prize for former MPI scientist
Physicist Ulrich Haeberlen contributed to the award-winning “Myon g-2” project through his research. July 16, 2026 An international research group has been awarded the “Breakthrough Prize for Fundamental Physics” for its decades of work on the “Myon g-2” particle physics experiment. Among the 387 laureates is a former researcher at the Max Planck Institute for […]
read more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies
Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]
read more
Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?
Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]
read more
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]
read more
VectorBuilder Advances Free VectorBee Software to Help Researchers Work with Greater Control and Flexibility
Major VectorBee update reflects VectorBuilder’s continued investment in free, researcher-first tools for genetic engineering and vector design. CHICAGO — July 14, 2026 — VectorBuilder, a global leader in gene delivery technologies, is launching a major update to VectorBee, its acclaimed 100% free DNA software created to help researchers view, edit, annotate, and analyze DNA and protein sequences with […]
read more
Beyond Cell Painting: From Phenotypic Screening To Mechanistic Understanding Using Antibody Panels
In the past decade, collaboration between the imaging community and biopharma discovery teams has led to methodologies and workflows that increase the capability, throughput, and automation of cellular imaging and analysis pipelines. Unlike hypothesis-driven approaches or conventional screening assays focused on narrow research questions and a few molecular targets, morphological profiling explores broader biological questions […]
read more
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]
read more
